Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that an arbitral tribunal (the “Tribunal”) of the International Chamber of Commerce Court of Arbitration (the “ICC”) has issued its Final Award (“Award”) in the arbitration dispute involving Neurochem Inc. and Neurochem (International) Limited (collectively, “Neurochem”) and Immtech Pharmaceuticals, Inc. (formerly known as Immtech International, Inc. (“Immtech”)). The dispute concerns an agreement entered into between Immtech and Neurochem Inc. in April 2002 (the “Agreement”) under which Neurochem Inc. had the right to apply its proprietary anti-amyloid technology to test certain compounds to be provided by Immtech. The ICC denied the majority of Immtech’s claims.
